Latest Articles
GSK reports promising early results in ovarian and womb cancer drug trial - The Guardian
GSK reports promising early results in ovarian and womb cancer drug trial The Guardian
Published: April 12, 2026, 10:52 p.m.
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive
Published: April 12, 2026, 9:35 p.m.
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM
GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO
GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WKZO
GSK sees blockbuster potential in targeted cancer therapy after promising early data WKZO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WSAU
GSK sees blockbuster potential in targeted cancer therapy after promising early data WSAU
Published: April 12, 2026, 8:44 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
Link copied to clipboard!